Results 61 to 70 of about 854 (146)
eNeurologicalSci, 2022 Primary headache disorders in particular migraine are one of the most common causes of disability worldwide. Given the high burden of migraine in terms of disability, there has been an effort to develop migraine specific therapies that has led to the ...
Oyindamola I. Ogunlaja, Peter J. Goadsby
doaj +1 more source
Lasmiditan: new drug for acute migraine [PDF]
, 2019 Migraine is ranked by the World Health Organization as the world’s second leading cause of disability. The current state of knowledge suggests that migraine is a neuronal process involving activation and sensitization of the trigeminal nociceptors and ...
Brashier, Dick +5 more
core +1 more source
Pharmaceutics, 2020 In the last few years, there have been significant advances in migraine management and prevention. Lasmiditan, ubrogepant, rimegepant and monoclonal antibodies (erenumab, fremanezumab, galcanezumab, and eptinezumab) are new drugs that were launched on ...
Danuta Szkutnik-Fiedler
doaj +1 more source
Migraine: Epidemiology, Risk Factors, Pathophysiology, and Treatment
MedComm, Volume 7, Issue 9, September 2026.Migraine is a highly prevalent, female‐predominant, and disabling brain disorder shaped by genetic susceptibility, hormonal influences, modifiable attack factors, and comorbidity‐related progression. This review integrates current evidence on migraine epidemiology, phase‐specific neurovascular and neuroglial mechanisms, including CGRP signaling and ...
Weiwei Lu +9 more
wiley +1 more source
Data from: Lasmiditan is an effective acute treatment for migraine A phase 3 randomized study
, 2018 Objective: To assess the efficacy and safety of lasmiditan in the acute treatment of migraine. Methods: Adult patients with migraine were randomized (1:1:1) to a double-blind dose of oral lasmiditan 200 mg, lasmiditan 100 mg, or placebo, and ...
Dozier, Gregory +5 more
core +1 more source
European Journal of Neurology, Volume 33, Issue 7, July 2026.In this prospective study of 623 adults with migraine treated with erenumab, baseline serum hs‐CRP and TNF‐α were not associated with treatment response. Serum TNF‐α increased modestly during treatment, but changes did not differ between responders and non‐responders.
William K. Karlsson +6 more
wiley +1 more source
, 2022 Additional file 2: Supplementary Figure 2. Involvement of the 5-HT1D receptors in the effect of Lasmiditan. Before the addition of 30 μM Lasmiditan, 1.25 μM of BRL15572, a 5HT1D receptor antagonist was added to the dura (n = 5) which subsequently ...
Karin Warfvinge (407987) +7 more
core +1 more source
Headache: The Journal of Head and Face Pain, Volume 66, Issue 7, Page 1628-1643, July/August 2026.Abstract Background Calcitonin gene‐related peptide (CGRP) is a key mediator in migraine pathophysiology, and the development of gepants, novel CGRP receptor antagonists, has expanded therapeutic options for both acute and preventive treatment. This scoping review aims to synthesize current evidence on the pharmacology, clinical applications, safety ...
Luigi Francesco Iannone +5 more
wiley +1 more source
Cerebrospinal Fluid and Plasma Concentrations of Atogepant in Humans
Clinical and Translational Science, Volume 19, Issue 6, June 2026.ABSTRACT The aim of this study was to determine the cerebrospinal fluid (CSF) to plasma concentration ratio of atogepant. Healthy adult participants (N = 28) were enrolled into this phase 1, open‐label study and received atogepant 60 mg once daily for 8 days. Steady‐state atogepant concentrations were determined from CSF samples collected on Day 6 at 2
Ramesh R. Boinpally, Joel M. Trugman
wiley +1 more source
Безопасность и риск фармакотерапииINTRODUCTION. Lasmiditan, a new selective 5-HT1F receptor agonist (approved by FDA in 2019), relieves migraine attacks via neuronal inhibition and acts in the central and peripheral nervous systems.
I. A. Mazerkina, R. N. Alyautdin
doaj +1 more source